Cushing's Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The cushing's syndrome market reached a value of USD 413.1 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 928.2 Million by 2035, exhibiting a growth rate (CAGR) of 7.67% during 2025-2035.

The Cushing's syndrome market has been comprehensively analyzed in IMARC's new report titled "Cushing's Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Cushing's syndrome is a medical condition that develops when the body is exposed to high levels of cortisol for a prolonged period. Several factors, such as the use of oral corticosteroids, the development of a benign tumor on the pituitary gland, or a tumor on the adrenal glands, can contribute to the illness. The signs and symptoms of Cushing's syndrome are wide-ranging and can affect different parts of the body. Some of the common indications include weight gain, fatigue and muscle weakness, high blood pressure, increased thirst, frequent urination, etc. Cushing's syndrome can be diagnosed using a combination of medical history, physical examination, and laboratory investigations. The 24-hour urinary free cortisol test is often used to diagnose the ailment as it measures the amount of cortisol in the urine over a 24-hour period. Cortisol levels can also be measured through blood testing, and a dexamethasone suppression test can assist in identifying whether a tumor or the adrenal glands are responsible for the production of cortisol.

The increasing intake of corticosteroids, either as medication or as part of medical treatment for conditions such as asthma, rheumatoid arthritis, lupus, etc., is primarily augmenting the global Cushing's syndrome market. In addition to this, the widespread adoption of radiation therapy to reduce the size of a pituitary gland tumor or to treat an adrenal gland tumor that cannot be removed surgically is also bolstering the market growth. Moreover, the emerging popularity of minimally invasive surgical techniques, including laparoscopic adrenalectomy, on account of their several benefits over traditional open surgeries, such as shorter hospital stays, faster recovery period, and less postoperative pain, is acting as a significant growth-inducing factor. Apart from this, the increasing utilization of combination therapy, which involves surgical intervention, medical treatment, and lifestyle changes to effectively manage cortisol levels, is also creating a positive outlook for the market. Furthermore, the introduction of improved delivery methods for medications, including long-acting injections, for enhanced adherence to medication regimens and better control of cortisol levels is expected to drive the global Cushing's syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Cushing's syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Cushing's syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Cushing's syndrome market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Cushing’s syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Cushing’s syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cushing's syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Cushing’s syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Cushing’s syndrome across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Cushing’s syndrome across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of Cushing’s syndrome across the seven major markets?
• What is the number of incident cases (2019-2035) of Cushing’s syndrome by age across the seven major markets?
• What is the number of incident cases (2019-2035) of Cushing’s syndrome by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of Cushing’s syndrome by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with Cushing’s syndrome across the seven major markets?
• What is the size of the Cushing’s syndrome patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend Cushing’s syndrome of?
• What will be the growth rate of patients across the seven major markets?

Cushing's Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Cushing’s syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Cushing’s syndrome market?
• What are the key regulatory events related to the Cushing’s syndrome market?
• What is the structure of clinical trial landscape by status related to the Cushing’s syndrome market?
• What is the structure of clinical trial landscape by phase related to the Cushing’s syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the Cushing’s syndrome market?